Financial News · Live Terminal

Page 72 of 362

BofA Securities Raises MongoDB Price Target to $450 From $390, Maintains Buy Rating

MongoDB (MDB) has an average rating of overweight and mean price target of $399.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $357.09, Change: $+6.35, Percent Change: +1.81%

$MDB

Wire21d ago

BofA Securities Adjusts Sandisk Price Target to $2,100 From $1,550, Maintains Buy Rating

Sandisk Corporation (SNDK) has an average rating of overweight and mean price target of $1,863.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $1625.00, Change: $+65.68, Percent Change: +4.21%

$SNDK

Wire21d ago

BofA Securities Adjusts Price Target on IBM to $315 From $300

IBM (IBM) has an average rating of overweight and mean price target of $295.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $285.78, Change: $+0.94, Percent Change: +0.33%

$IBM

Wire21d ago

BofA Securities Adjusts Price Target on NetApp to $180 From $150

NetApp (NTAP) has an average rating of overweight and mean price target of $171.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $169.52, Change: $+2.48, Percent Change: +1.48%

$NTAP

Wire21d ago

Market Chatter: Uber's Delivery Hero Pursuit Faces Challenge From Saudi Startup

Uber Technologies' (UBER) efforts to acquire Delivery Hero could face a new hurdle as Saudi Arabia-based quick-commerce startup Ninja is considering a bid for some of the German food delivery company's Middle East assets, the Financial Times reported Monday, citing people familiar with the matter.Ninja is initially focused on acquiring Delivery Hero's Saudi subsidiary HungerStation and could submit a proposal to the company's board as early as this week. The startup is also exploring a partnership with another group to acquire parts of Talabat, the Dubai-based food-delivery platform, the people said, according to the report.Some Delivery Hero shareholders would support offers of around 10 billion euros ($11.5 billion) for the two assets, with Talabat accounting for most of that value, the report said. Such a deal could complicate Uber's takeover ambitions, given that the US ride-hailing company recently valued Delivery Hero at roughly 12 billion euros.The companies didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $70.28, Change: $-0.43, Percent Change: -0.61%

$UBER

Wire21d ago

Skillz Plans to Change Corporate Name to Firy

Skillz (SKLZ) said Monday that it intends to change its corporate name to Firy Inc. on June 18 and expects its Class A shares to begin trading under the ticker symbol "FIRY" on the New York Stock Exchange on June 22.The company, a mobile games platform, said shareholders do not need to take any action in connection with the name and ticker change.Skillz shares were more than 8% higher in Monday trading.Price: $8.90, Change: $+0.47, Percent Change: +5.58%

$SKLZ

Wire21d ago

Constellium Se Insider Sold Shares Worth $280,080, According to a Recent SEC Filing

John Ormerod, Director, on June 04, 2026, sold 8,000 shares in Constellium Se (CSTM) for $280,080. Following the Form 4 filing with the SEC, Ormerod has control over a total of 24,873 ordinary shares of the company, with 24,873 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1563411/000156341126000180/xslF345X05/wk-form4_1780925664.xmlPrice: $34.06, Change: $+0.17, Percent Change: +0.50%

$CSTM

Wire21d ago

Uber's Delivery Hero Pursuit Faces Challenge From Saudi Startup, Financial Times Reports

$UBER

Wire21d ago

Wedbush Adjusts Tango Therapeutics PT to $39 From $33, Maintains Outperform Rating

Tango Therapeutics (TNGX) has an average rating of overweight and mean price target of $31.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $27.06, Change: $+6.84, Percent Change: +33.83%

$TNGX

Wire21d ago

Carlyle-Managed Funds Complete Acquisition of Majority Stake in MAI Capital Management

Funds managed by Carlyle (CG) have completed their acquisition of a majority stake in investment advisor MAI Capital Management effective June 4, MAI said Monday.The deal was valued at more than $2.8 billion, according to an earlier statement.Galway Holdings, funds managed by Harvest Partners, and Oak Hill Capital have exited their positions in MAI with the closing of the transaction, MAI said.Price: $43.11, Change: $-0.38, Percent Change: -0.86%

$CG

Wire21d ago

EXoZymes Prices $5.3 Million Offering

EXoZymes (EXOZ) has priced its public offering of units, consisting of two shares of common stock and one common stock purchase warrant, at $18 per unit, with estimated gross proceeds of $5.3 million, the company said Monday.The company also granted the underwriter a 45-day option to purchase up to 44,420 units at the offering price, it said.Proceeds will be used to further develop N-trans-caffeoyltyramine opportunities associated with EXoZymes' NCT business, the company said.The offering is slated to close on Tuesday.Shares of the company were up 5.4% in early Monday trading.Price: $9.49, Change: $+0.49, Percent Change: +5.44%

$EXOZ

Wire21d ago

Polyrizon Advances Nasarix Study With 3 Major US Trial Sites

Polyrizon (PLRZ) has secured agreements with three US clinical sites for its upcoming Nasarix trial, marking a key step toward initiating its multi-center study in seasonal allergic rhinitis, the company said Monday.The sites represent major enrollment centers expected to support patient recruitment for the study evaluating the safety, tolerability and efficacy of its intranasal hydrogel allergy blocker.Polyrizon said the trial will compare Nasarix with saline spray in patients with seasonal allergic rhinitis, with up to five US sites expected to participate in total.Shares of Polyrizon were down more than 3% in Monday trading.Price: $12.73, Change: $-0.48, Percent Change: -3.63%

$PLRZ

Wire21d ago

BOS Better Online Solutions Says US, India Orders Rise to $7.1 Million

BOS Better Online Solutions (BOSC) said Monday it received $7.1 million in combined orders from the US and India in the first five months of 2026, up from about $1.5 million a year earlier.Orders from India rose to $4.3 million from $850,000 in the same period a year ago, while US orders increased to $2.8 million from $650,000, the company said.Chief Executive Eyal Cohen said the company expects 2026 revenue to surpass $51 million.Shares of BOS Better Online Solutions were up 3% in early Monday trading.Price: $4.28, Change: $+0.13, Percent Change: +3.04%

$BOSC

Wire21d ago

Lixiang Education Regains Compliance With Nasdaq Market-Value Requirement; Shares Fall 10%

Lixiang Education (LXEH) shares were down more than 10% in Monday trading after it said it has regained compliance with Nasdaq Stock Market listing rules.The company said it met the criteria by having a minimum market value of publicly held shares of $5 million for at least 10 consecutive business days.Lixiang Education had been notified by Nasdaq in February that it had fallen out of compliance with its listing rules.Price: $1.17, Change: $-0.13, Percent Change: -10.00%

$LXEH

Wire21d ago

Enigmatig Says Internal Review Finds No Cause for Recent Share Volatility

Enigmatig (EGG) said Monday an internal review found no undisclosed material developments or other factors that would explain recent volatility in its shares.The company said it issued the statement in accordance with NYSE American requirements following unusual trading activity in its shares on June 4 and June 5.Shares of the company were over 14% higher in early trading Monday.Price: $6.30, Change: $+0.79, Percent Change: +14.34%

$EGG

Wire21d ago

IQSTEL Board Approves Share Buyback Program

IQSTEL (IQST) said Monday its board has approved a share buyback program of up to 1 million shares.The company said the program will be backed by cash dividends received from QXTEL, one of its operating subsidiaries.Price: $1.09, Change: $+0.12, Percent Change: +12.81%

$IQST

Wire21d ago

EHang Board Approves Up to $30 Million Share Buyback Plan

EHang's (EH) board has approved the buyback of up to $30 million of American Depositary Shares or ordinary shares, the company said Monday.The company said the buybacks may take place from time to time over the next 12 months and are expected to be funded mainly from its existing cash balance.Shares of the company were up more than 6% in Monday's premarket trading.

$EH

Wire21d ago

AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell

AIM ImmunoTech (AIM) said Monday that its metastatic pancreatic cancer drug Ampligen has shown "positive progress" in an ongoing phase 2 study.According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.Shares of AIM rose more than 26% in recent premarket trading Monday.Price: $0.6520, Change: $+0.135, Percent Change: +26.02%

$AIM

Wire21d ago

CaliberCos Shares Rise Over 2% as CFO Jade Leung to Step Down, Michael Rosales Named Acting Finance Chief

CaliberCos (CWD) shares rose more than 2% in premarket trading Monday after the company said late Friday that Chief Financial Officer Jade Leung will step down to pursue another opportunity.The company said the departure is not related to any disagreement over operations, accounting practices or financial reporting. CaliberCos also reaffirmed its full-year 2026 guidance, stating that the leadership transition will not affect its strategy or financial outlook.Caliber appointed Michael Rosales as acting CFO, effective June 14. Rosales currently serves as Senior Vice President of Accounting, Financial Reporting & Tax and has been with the company since 2020, it said.The company said its board has launched a search for a permanent CFO and will consider both internal and external candidates.

$CWD

Wire21d ago

Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-Bell

Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat, an investigational PRMT5 inhibitor, in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.As of May 28, 59 patients with previously treated MTAP-deleted and RAS-mutant pancreatic ductal adenocarcinoma or non-small cell lung cancer had been treated with a vopimetostat-based combination either daraxonrasib or zoldonrasib, the company said.In the vopimetostat plus daraxonrasib dose-escalation arm, patients received either 200 mg or 250 mg of vopimetostat once daily together with 100 mg of daraxonrasib once daily. The company reported a 92% objective response rate and a 90% six-month progression-free survival rate in patients with MTAP-deleted and RAS-mutant pancreatic ductal adenocarcinoma. Tango also reported a 100% objective response rate in patients with non-small cell lung cancer.In the vopimetostat plus zoldonrasib dose escalation arm, patients with PDAC received vopimetostat 200 mg or 250 mg QD plus zoldonrasib 600 mg or 1200 mg QD. Data showed a 52% of objective response rate and 74% six-month PFS rate.The vopimetostat plus daraxonrasib or combination combination were generally well tolerated across all dose levels, with no new safety signals observed, the company said.Tango said it plans in the second half of the year to finalize the design of a phase 3 randomized controlled trial of the combination approach in pancreatic cancer, release vopimetostat monotherapy data in lung cancer and initial TNG456 glioblastoma data, present second- and third-line pancreatic cancer combination data at a scientific conference, and begin a phase 1/2 study of vopimetostat in combination with ERAS-0015.Shares of the company were up more than 44% in premarket trading Monday.Price: $29.30, Change: $+9.08, Percent Change: +44.91%

$TNGX

Showing 1421-1440 of 7236

Wire21d ago

Tango Therapeutics Says Initial Results From Phase 1/2 Trial of Pancreatic Cancer Drug Candidate Showed Improvement in Survival Rate; Shares Rise Pre-Bell

$TNGX